Vermillion, Inc. (VRML) Downgraded to “Sell” at ValuEngine
ValuEngine lowered shares of Vermillion, Inc. (NASDAQ:VRML) from a hold rating to a sell rating in a research report sent to investors on Friday.
Shares of Vermillion (NASDAQ:VRML) opened at 1.50 on Friday. The stock’s market capitalization is $84.13 million. The stock’s 50 day moving average is $1.76 and its 200-day moving average is $1.81. Vermillion has a 12-month low of $0.76 and a 12-month high of $2.85.
Vermillion (NASDAQ:VRML) last released its quarterly earnings results on Thursday, May 18th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by $0.01. Vermillion had a negative return on equity of 195.68% and a negative net margin of 443.29%. The firm had revenue of $0.73 million for the quarter. On average, analysts expect that Vermillion will post ($0.16) earnings per share for the current year.
Institutional investors have recently added to or reduced their stakes in the company. Birchview Capital LP boosted its stake in Vermillion by 1.3% in the first quarter. Birchview Capital LP now owns 2,752,933 shares of the company’s stock valued at $5,649,000 after buying an additional 35,419 shares during the period. M&T Bank Corp boosted its stake in Vermillion by 48.2% in the first quarter. M&T Bank Corp now owns 230,500 shares of the company’s stock valued at $482,000 after buying an additional 75,000 shares during the period. Greenwich Wealth Management LLC bought a new stake in Vermillion during the first quarter valued at about $276,000. Finally, Oracle Investment Management Inc. boosted its stake in Vermillion by 7.2% in the first quarter. Oracle Investment Management Inc. now owns 9,241,956 shares of the company’s stock valued at $19,316,000 after buying an additional 617,731 shares during the period. 36.44% of the stock is owned by hedge funds and other institutional investors.
Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.